News

The companies will collaborate on the development of GLIX1 as a potential treatment for both newly diagnosed and recurrent GBM. This molecule functions by enhancing TET2 activity within

The submission draws on findings from the TEMPO clinical development programme, which assessed the tolerability, efficacy, and safety of tavapadon in various populations with Parkinson’s disease. This programme

The approval applies to individuals with confirmed amyloid pathology who are apolipoprotein E (ApoE4) heterozygotes or non-carriers. Kisunla, administered as a monthly infusion, is already available in several

The launch follows approval from the US Food and Drug Administration (FDA). Iron sucrose is a key treatment for iron deficiency anaemia, affecting around five million people in

The drug is indicated for adults with mild cognitive impairment or mild dementia, who are non-carriers or heterozygotes of apolipoprotein E ε4 (ApoE ε4) with confirmed amyloid pathology.

The total capital raised by the company now stands at $446m, following a $386m series A/A-1 financing announced in November 2024. The series B round was led by

Tremfya is a fully-human, dual-acting monoclonal antibody that works by selectively targeting IL-23, a protein involved in abnormal immune activity. The drug is already approved in the US

ThecaFlex DRx is an investigational implantable device to deliver antisense oligonucleotides (ASOs) intrathecally. The device administers medicines to patients with neurologic disorders. It is designed to offer an

This authorisation is specifically for patients who have symptomatic TGCT, with significant physical functional decline, and for whom surgical intervention is either not an option or would lead